(Circulation. 1997;95:1549-1553.)
© 1997 American Heart Association, Inc.
Articles |
From the Department of Cardiology (I.D.S., K. Wang, K. Wilczek, J.P., F.V.D.W.), Gasthuisberg, University Hospital, Leuven, Belgium; and Department of Vascular Pharmacology (D.M., R.V.A., G.V.), Organon International BV, Oss, The Netherlands.
Correspondence to I. De Scheerder, MD, PhD, Gasthuisberg University Hospital, Department of Cardiology, Herestraat 49, 3000 Leuven, Belgium.
| Abstract |
|---|
|
|
|---|
Methods and Results Thrombogenicity of metallic coronary stents (four heparin-coated and eight bare stents) was studied in a rat arteriovenous shunt model with the use of 125I-labeled fibrinogen and 51Cr-labeled platelets. Total clot weight after 30-minute follow-up was significantly lower in the heparin-coated stents compared with the bare stents (8.1±3.7 versus 25.8±4.6 mg; P<.001). Relative 125I and 51Cr activities in the stents were significantly higher in the bare stents than in the heparin-coated stents (125I, 1.03±0.43 versus 0.18±0.04, P=.003; 51Cr, 17.5±6.8 versus 4.4±1.0, P=.004). Subsequently, heparin-coated and bare stents were randomly implanted in the right coronary artery of 20 domestic pigs. Angiographic parameters were similar between both groups at baseline and after 6-week follow-up. Morphometry also did not show a significant difference in lumen area (bare, 1.03±0.83 mm2; heparin-coated, 1.12±0.73 mm2; P=NS) or neointimal hyperplasia (bare, 1.01±0.81 mm2; heparin-coated, 1.21±0.57 mm2; P=NS).
Conclusions Heparin coating of metallic coronary stents decreases their thrombogenicity but does not improve late vessel patency and neointimal hyperplasia at follow-up in a porcine coronary model.
Key Words: stents heparin thrombus stenosis
| Introduction |
|---|
|
|
|---|
Early clinical experience revealed frequent thrombotic stent closure and abundant healing response, resulting in a more pronounced neointimal hyperplasia compared with conventional balloon angioplasty.2 3 4 5 6 Optimal stent implantation and the use of antiplatelet treatment instead of full anticoagulation significantly decreased thrombotic complications after stent implantation.
Recently, heparin-coated stents were clinically introduced to further decrease in-hospital complications. In the present study, we compare the thrombogenicity of heparin-coated stents with that of bare metallic stents. Furthermore, we evaluate the potential beneficial effect of heparin coating on the increased hyperplastic response to the implanted metallic stent.
| Methods |
|---|
|
|
|---|
For the present animal experiments, the stents were coated with Duraflo II heparin (Bentley, Baxter Healthcare Corp).
The Duraflo II coating consists of unfractionated USP heparin and a hydrophobic binding agent. The binding agent is incorporated into the structure of heparin in such a way that the modification affects the physicochemical but not the biological properties of heparin. A submicronic layer of coating was applied to all surfaces of the stent.9 10 11
Stent Thrombogenicity in a Rat Arteriovenous Shunt Model
Heparin-coated (n=4) and bare stainless steel (n=8) stents were
deployed in an arteriovenous shunt (internal diameter, 2.0 mm)
that was connected between the left carotid artery and the right
jugular vein of male Wistar Hsd/Cpb rats (body weight, 300 to 340
g). The thrombogenicity of the stents was considered to be related to
the radioactivity measured in the inserted cannula after systemic
administration of 125I-labeled fibrinogen and
51Cr-labeled platelets.
After the rats were anesthetized with sodium pentobarbital (60 mg/kg IP), the left carotid artery and the right jugular vein were exposed from the surrounding tissue. The prepared arteriovenous shunt, which was filled with saline, was inserted into the jugular vein and the opposite carotid artery, after which blood circulation via the shunt was started. The segment of the shunt containing the stent was positioned between two detectors that continuously measured the radioactivity of the 51Cr-labeled platelets and 125I-labeled fibrinogen. Blood circulation was monitored by the continuous measurement of the blood flow according to the Doppler flow technique. Blood circulation was allowed for 30 minutes, during which none of the cannulas occluded. Continuous measurements of 51Cr-labeled platelets and 125I-labeled fibrinogen deposition were obtained using the Mumed automated isotope measuring system. At the end of the experiment, the thrombus, removed from the shunt, was characterized by weight and by its 51Cr-labeled platelet and 125I-labeled fibrinogen content. The latter two parameters were measured as the ratio of radioactivity of the clot to the radioactivity of the blood before insertion of the arteriovenous shunt.
Labeling of fibrinogen was performed according to the lactoperoxidase method described by Marchalonis.12 Clottable human fibrinogen (Kabi), 10 to 15 µg per rat, was labeled with 18.5 MBq of I-125 NEZ-033a (E.I. Dupont de Nemours GmBH) and stored in fractions of 150 µL each at -70°C until use to obtain 0.04 to 0.06 MBq for each rat at the day of injection. On the day of the experiment, 1 mL of saline was added to one fraction of 125I-labeled fibrinogen, after which 0.1 mL per rat was injected before insertion of the arteriovenous shunt.
Labeling of platelets was performed according to the method described by Meuleman et al.13 On the day before the experiment, platelets were harvested from donor rats (one donor for two acceptor rats) and labeled with [51Cr]Na2CrO4 (Amersham), 0.9 to 1.7 x 109 platelets, corresponding to 0.4 to 0.8 MBq of 51Cr. Labeling efficiency was 50%. Recovery after 1.5 hours of blood circulation in the rat was 80% to 100%.
Stent Thrombogenicity and Neointimal Response in a Porcine
Coronary Model
Stent implantation in the right coronary artery of domestic
crossbred pigs was performed according to the method described by De
Scheerder et al.14 15
In the first series of experiments, the presence of mural thrombi was studied 7 days after stent implantation. Either a heparin-coated or a bare stent was randomly placed in the right coronary artery of 20 pigs. At 7-day follow-up, quantitative coronary angiography was performed. The pigs were killed with an intravenous bolus of 10 mL of oversaturated potassium chloride. The right coronary artery was harvested for visual inspection of the stent.
In a second series of 20 experiments, the degree of foreign body reaction that occurred at 6 weeks after stent implantation was studied. Either a heparin-coated or a bare stent was randomly deployed in the right coronary artery of 20 pigs. At 6-week follow-up, final angiograms were obtained. The pigs were killed, and the right coronary artery was harvested for histopathology and morphometry. For these late follow-up studies, instrumentation of the pigs and angiographic techniques were identical to those used during the implantation procedure with the exception of intubation with a tracheotomy.
Measurements
Quantitative Coronary Angiography
Angiographic analysis of stented vessel segments was performed
before and immediately after stenting and at follow-up with the
Polytron 1000 system. The Polytron 1000 system was previously validated
in vitro and in vivo16 17 18 with a metal bar as a
calibration device.19 The diameter of the stented vessel
segments was measured. The degree of oversizing was expressed as the
ratio of balloon to artery thickness.
Histopathology and Morphometry
After the 6-week follow-up, the pigs were killed, and the
stented coronary segments were carefully dissected together with a 1-cm
minimum vessel segment both proximal and distal to the stent. The
segment was fixated in a 2% formalin solution. The stent filaments
were removed with the use of a stereomicroscope to avoid distortion of
or damage to the artery. Sections from each arterial segment were
stained with hematoxylin and eosin, van Gieson's elastic,
phosphotungstic acid hematoxylin, and Masson's trichrome stains. Light
microscopic examination was performed by an experienced pathologist who
was blinded to whether coating was applied. Morphometric analysis of
the coronary segments harvested was performed with the use of
morphometry software (Leitz CBA 8000). Measurements of maximal intimal
thickening and of the areas within the lumen (lumen area) and inside
the internal elastic lamina (intimal area) were performed on the
arterial sites, being visually appreciated as the most
proliferative.
Statistical Analysis
Thrombogenicity of the heparin-coated and bare stents was
compared with the use of unpaired Student's t tests.
Thrombotic events after stent implantation were compared with the use
of a
2 test. Arteriographic measurements before,
immediately after, and 6 weeks after stent implantation were compared
using paired Student's t tests. Comparison of both study
groups was performed using unpaired Student's t tests. Data
are presented as mean±SD. A value of P<.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
Stent Thrombogenicity in Porcine Coronary Arteries
A total of 10 heparin-coated and 10 bare stents were randomly
implanted in the right coronary artery of 20 pigs. The angiographic
measurements obtained in the stents before, immediately after, and at 7
days after implantation are presented in Table 2
; no
significant differences between stent types were observed. However,
after the animals were killed, visual inspection of the stents revealed
mural thrombi in 8 bare stents but only 2 heparin-coated stents
(P<.02).
|
Foreign Body Reaction Provoked by Stent Implantation in Porcine
Coronary Arteries
In a second series of experiments, a total of 10 heparin-coated
and 10 bare stents were again randomly implanted in the right coronary
artery of 20 pigs. There were no significant differences in the
angiographic measurements obtained before, immediately after, and at 6
weeks after stent implantation (Table 3
). Similarly, the
postmortem morphometric analysis showed no difference in the different
transversal areas measured at the most reactive intrastent site (Table 4
). Phosphotungstic acid hematoxylin staining was
positive in 9 of the bare metallic stents compared with 2 of the
heparin-coated stents (P<.002).
|
|
| Discussion |
|---|
|
|
|---|
When a heparin-coated stent was implanted in a shunt connecting
the carotid artery and jugular vein of Wistar rats, less clot formation
was found than after implantation of a bare metallic stent. This
observation was reflected in reduced accumulation of radioactive
fibrinogen and platelets and a smaller thrombus. Subsequently, when the
stents were implanted in normal porcine right coronary arteries, after
7 days, mural thrombi were found in eight bare metallic stents but only
two heparin-coated stents (Fig 3
). These results are
concordant with the data recently published by Hårdhammar et
al,20 who used another type of heparin coating and
demonstrated a significant decrease in subacute thrombotic occlusions
in the heparin-coated stents.
|
These observations are clinically relevant. Early clinical experience with coronary stents was hampered by early thrombotic stent occlusion resulting in an unacceptable morbidity and even mortality. Optimal stent implantation with intravascular ultrasound and/or high-pressure stent deployment21 and the use of antiplatelet treatment22 23 instead of full anticoagulation significantly decreased this dramatic complication. High-pressure stent deployment, however, can be complicated by distal dissection and increased vessel injury resulting in a more pronounced neointimal hyperplasia,24 and the use of ticlopidine may be limited by systemic hematological side effects. Therefore, heparin-coated stents could represent an attractive alternative, especially in small vessels and more diffuse coronary disease, in which multiple stents or single long stents are needed.
Our longer-term experiments show that after 6 weeks, no difference was
present between the intrastent diameters of the heparin-coated and bare
stents, as measured either angiographically or morphometrically. This
finding may be surprising because earlier experimental studies suggest
that platelets, thrombin, and mural thrombosis are involved in the
restenosis process.25 26 Fig 3
shows an example of mural
thrombi formation surrounding the stent filaments. Fig 4
shows an organized mural thrombus at 6-week follow-up, suggesting the
important role that organization of mural thrombi might play in the
restenosis process. Our results are concordant with the results of
Hårdhammar et al.20 They demonstrated a significantly
thicker neointima in the heparin-coated stent group compared with the
bare stent group after 4-week follow-up. This difference, however,
became insignificant after 12-week follow-up. These findings open the
debate on the real importance of platelet adhesion and mural thrombi
formation on neointimal hyperplasia after stent implantation. After
balloon angioplasty, organization of mural thrombi seems to play a
major role in the restenosis process. This study suggests, however,
that this is less so after stent implantation. Other factors, such as
deep injury caused by the deployment of the stent in the diseased
artery and a foreign body response caused by the implantation of a
foreign body, are potentially more important in the pathogenesis of
neointimal hyperplasia after stent implantation.
|
Conclusions
This study demonstrates that heparin coating of metal coronary
stents reduces their thrombogenicity but does not influence the
neointimal hyperplasia.
| Acknowledgments |
|---|
Received July 23, 1996; revision received October 14, 1996; accepted November 4, 1996.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. N. Helmus, D. F. Gibbons, and D. Cebon Biocompatibility: Meeting a Key Functional Requirement of Next-Generation Medical Devices Toxicol Pathol, January 1, 2008; 36(1): 70 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Lee, J. E. Lee, K. W. Lee, H. Y. Nam, H. J. Jeon, Y. J. Sung, J. S. Kim, H. J. Lim, J.-s. Park, J. Y. Ko, et al. Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2800 - 2804. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mehran, E. D. Aymong, D. T. Ashby, T. Fischell, H. Whitworth Jr, R. Siegel, W. Thomas, S. C. Wong, R. Narasimaiah, A. J. Lansky, et al. Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent: Final Results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) Study Circulation, September 2, 2003; 108(9): 1078 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF] |
||||
![]() |
A. Kastrati, H. Schuhlen, and A. Schomig Stenting for small coronary vessels: a contestable winner J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1604 - 1607. [Full Text] [PDF] |
||||
![]() |
P.J. de Feyter The quest for the ideal stent Eur. Heart J., October 1, 2001; 22(19): 1766 - 1768. [PDF] |
||||
![]() |
J Wohrle, E Al-Khayer, U Grotzinger, C Schindler, M Kochs, V Hombach, and M Hoher Comparison of the heparin coated vs the uncoated Jostent(R)--no influence on restenosis or clinical outcome Eur. Heart J., October 1, 2001; 22(19): 1808 - 1816. [Abstract] [PDF] |
||||
![]() |
D. E. Drachman, E. R. Edelman, P. Seifert, A. R. Groothuis, D. A. Bornstein, K. R. Kamath, M. Palasis, D. Yang, S. H. Nott, and C. Rogers Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2325 - 2332. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Baron, A. H. Gershlick, K. Hogrefe, J. Armstrong, C. M. Holt, R. K. Aggarwal, M. Azrin, M. Ezekowitz, and D. P. de Bono In vitro evaluation of c7E3-Fab (ReoProTM) eluting polymer-coated coronary stents Cardiovasc Res, June 1, 2000; 46(3): 585 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Verheye, C. P. Markou, M. Y. Salame, B. Wan, S. B. King III, K. A. Robinson, N. A. F. Chronos, and S. R. Hanson Reduced Thrombus Formation by Hyaluronic Acid Coating of Endovascular Devices Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 1168 - 1172. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Gunn and D Cumberland Stent coatings and local drug delivery. State of the art Eur. Heart J., December 1, 1999; 20(23): 1693 - 1700. [PDF] |
||||
![]() |
E. R. Edelman and C. Rogers Stent-Versus-Stent Equivalency Trials : Are Some Stents More Equal Than Others? Circulation, August 31, 1999; 100(9): 896 - 898. [Full Text] [PDF] |
||||
![]() |
H. M. Nugent, C. Rogers, and E. R. Edelman Endothelial Implants Inhibit Intimal Hyperplasia After Porcine Angioplasty Circ. Res., March 5, 1999; 84(4): 384 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. F. Bertrand, R. Sipehia, R. Mongrain, J. Rodes, J.-C. Tardif, L. Bilodeau, G. Cote, and M. G. Bourassa Biocompatibility aspects of new stent technology J. Am. Coll. Cardiol., September 1, 1998; 32(3): 562 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamawaki, H. Shimokawa, T. Kozai, K. Miyata, T. Higo, E. Tanaka, K. Egashira, T. Shiraishi, H. Tamai, K. Igaki, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo J. Am. Coll. Cardiol., September 1, 1998; 32(3): 780 - 786. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |